BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL50

- MitoImmune initiates a Phase 2 trial of oral mucositis (OM) prevention in the first half of 2021 in the US and Korea, and is expanding OM treatment into hematopoietic stem cell transplantation clinical trials

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson,

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, today announced the addition of seasoned life sciences executive, Dieter Weinand , to its Board of Directors.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13,

Enzychem Lifesciences (KOSDAQ: 183490), announced today that it has completed patient enrollment in Stage 2 of its Phase 2 clinical trial of EC-18 in chemoradiation induced oral mucositis (CRIOM).

Brings prior experience as US Representative to the World Health Organization Executive Board and expertise in health care delivery, health policy, international affairs and pandemic influenza planning to FluroTest team

Alnylam to Webcast Presentation at 20 th Annual Needham Virtual Healthcare Conference

OSE Immunotherapeutics announced the first peer-reviewed publication on OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in Science Advances.

Collaboration will focus on identifying microbiome therapeutics for enhancing response to and reducing adverse effects of checkpoint inhibitors in melanoma patients